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Table. Patient Characteristics
Patient Age/Sex Pre-SCT Karyotype
Time from
Dx to SCT SCT type/ Prep/ GVHD px Follow-up Post-SCT Genetic Studies
1 46 M 46,XY,t(9;22)[12],
47,XY,18 [2], 46,XY[3],
46,XY,1Y,-7[3]
16 months MSD/ Bu1Cy / CSA1MTX 16 months Bcr-Abl PCR: negative,
FISH for -7: negative
2 48 F 46,XX,t(9;22)[17], 45,XX,-7[3] 19 months MUD/ Bu1Cy / Tacrolimus1MTX 17 months Bcr-Abl PCR: negative
3 48 M 46,XY[3], 46,XY,t(9;22)[9],
47,XY,18[1], 45,XY,-7[7]
30 months MUD/ Bu1Cy / CSA1MTX 20 months Bcr-Abl PCR: negative
Abbreviations: Dx, diagnosis, M, male; F, female; SCT, stem cell transplant; Prep, preparative regimen; GVHD px, graft versus host disease prophylaxis;
CSA, cyclosporine; MTX, methotrexate; MSD, matched sibling donor; MUD, matched unrelated donor; PCR, polymerase chain reaction; FISH; fluores-
cence in situ hybridization.
Poster Session II S297Results: As of July 2009 68% of 107 reponders completed the sur-
vey, 100 could read dutch and 7 filled out the english version. 69%
were women. 45% were patients, 24% family members, 21% were
neither patient nor family member. 19% had leukemia, 7% lym-
phoma, 10% multiple myeloma, 22% breast cancer, 14% another
type of cancer and 13% had no cancer. 39% had developed cancer
in the past three years.
38% of responders knew what autologous and 42% what alloge-
neic transplantation is. 29% knew that autologous and 29% that al-
logeneic transplants were possible treatment options. 21% had
spoken with a doctor about autologous and 20% about allogeneic
transplant. 9% had been treated by autologous and 9% by allogeneic
transplantation. 26% were interested to receive more information
about transplantation.
55% was aware that bone marrow can be donated. The cost
estimate was in all but two responders far below the actual costs
of the procedures. Only 2% of responders was interested to
make a donation to support research in transplantatation and
24% were uncertain. 42% were not interested to donate for
research.
Discussion: Herein results are presented of responses to a website
questionnaire. Through time 107 people have responded and only
45% were patient. This is a small percentage of patients who have
seen the invitation to respond either at the website or a public site.
Our survey shows that bone marrow transplantation is considered
a treatment and not research.378
SUCCESSFUL ALLOGENEIC STEM CELL TRANSPLANTATION OF PATIENTS
WITH CML AND MONOSOMY 7
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Patients with chronic myeloid leukemia (CML) whose Phila-
delphia chromosome-positive [Ph+] cells harbor additional cyto-
genetic abnormalities have been cured with allogeneic stem cell
transplantation (SCT). Although abnormalities in Ph- cells are
often transient and innocuous, loss of chromosome 7 is a harbin-
ger of poor-prognosis myelodysplastic syndrome (MDS) and, ul-
timately, transformation to acute myeloid leukemia (AML). SCT
is potentially curative for patients with coexistent CML and
MDS with monosomy 7, however, there are no reported data
on outcomes of such patients who have undergone SCT. We
retrospectively identified three patients with CML who subse-
quently developed monosomy 7 in Ph- cells. All three were suc-
cessfully treated with SCT. Their characteristics and outcome
are listed in the Table. All three were initially treated with
imatinib, but had suboptimal responses with persistent myelo-
suppression and subsequent development of monosomy 7 in
Ph- cells. Patients with CML who have suboptimal responses
and myelosuppression during therapy with imatinib are at risk
for development of monosomy 7 in Ph- cells. Early identifica-
tion of such patients allows for potentially curative SCT beforethe development of AML. We conclude that coexistent Ph+
CML and Ph- MDS with monosomy 7 can be successfully
treated with allogeneic SCT. Further follow-up is needed to de-
termine long-term outcomes.379
ISOLATED EPSTEIN-BARR VIRUS-INDUCED CENTRAL NERVOUS SYSTEM
POST-TRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER DESPITE
NEGATIVE SERUM PCR
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Esptein-Barr virus (EBV)-induced post-transplant lymphopro-
liferative disorder (PTLPD) is a well recognized complication
of hematopoietic and solid organ transplantation. Central ner-
vous system (CNS) localization in the absence of systemic dis-
ease is rare. In addition, most cases are associated with rising
EBV viral load in the serum. Indeed, positive EBV PCR assay
on the serum was found to have a negative predictive value of
93%. Therefore, clinicians have been relying on such testing
to monitor patients at risk and administer preemptive therapy
with rituximab.
We report a patient who developed CNS space-occupying le-
sion six months following bone marrow transplantation from an
unrelated donor with A allele mismatch for recurrent acute mye-
logenous leukemia. The patient conditioning regimen had in-
cluded fludarabine, melphalan, and rabbit ATG. The patient
course had been significant for severe acute graft-versus-host dis-
ease requiring multiple immunosuppressive agents including ritux-
imab. The lesion was biopsied and proven to represent EBV
positive diffuse large B cell-lymphoma. An extensive staging
work-up failed to reveal any evidence of systemic disease. All pre-
vious studies on the serum for EBV by PCR had been negative as
was repeat testing at the time of diagnosis. EBV however was de-
tected in the CSF.
The discovery of an EBV-driven isolated CNS PTLD in our pa-
tient is unusual in that there was no evidence of EBV in the periph-
eral blood by PCR. Two similar cases have been reported in the
literature.
The nature of this phenomenon is uncertain. One plausible ex-
planation is the effectiveness of rituximab in clearing the virus
from the peripheral blood but not from the CNS given its
poor blood-brain barrier penetration. If this was the case, one
might fear an increase in the incidence of CNS localization of
PTLD as clinicians increasingly rely on the use of rituximab in
face of rising EBV viral load in the peripheral blood. In summa-
tion we believe that clinicians should be aware of the potential
for CNS PTLD in the absence of PCR-evidence of EBV reacti-
vation in peripheral blood in patients treated with rituximab. Ef-
forts must continue to develop alternative approaches to
preemptive treatments of EBV reactivation such as adoptive
immunotherapy.
